Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface
Aggressive B-Cell Non-Hodgkin Lymphoma
Explore 28 assets in Aggressive B-Cell Non-Hodgkin Lymphoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04231747CT.gov A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Aggressive B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface (this asset) | Juno Therapeutics, a Subsidiary of Celgene | P1 | CC · 47 |
| Rituximab | Shanghai EpimAb Biotherapeutics Co., Ltd. | P3 | BB |
| Lipegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | BB |
| (+)-Vincristine | Universität des Saarlandes | P3 | B |
| Pegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | B |
| Acalabrutinib | Patrick C. Johnson, MD | P2 | B |
| Zanubrutinib | Prelude Therapeutics | P2 | B |
| Obinutuzumab | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Oxaliplatin | Shanghai EpimAb Biotherapeutics Co., Ltd. | P2 | B |
+42 more in the Aggressive B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P1 | CC · 47 |
| Non-Hodgkin Lymphoma | — | P1 | CC · 46 |
| Myasthenia Gravis | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface in Aggressive B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bms-986353-is-an-investigational-cd19-targeted-car-t-cell-product-the-cd19-specific-car-consists-of-a-single-chain-variable-fragment-scfv-binding-domain-derived-from-a-cd19-specific-monoclonal-antibody-mab-fmc63-an-igg-derived-hinge-region-a-cd28-transmembrane-domain-and-the-cd137-41bb-and-cd3-chain-signaling-domains-the-third-generation-sin-lentiviral-vector-which-encodes-the-car-domains-described-above-also-encodes-a-truncated-human-epidermal-growth-factor-receptor-egfrt-that-is-expressed-separately-from-the-cd19-car-on-the-t-cell-surface-aggressive-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →